Publication | Closed Access

Dapagliflozin protects heart function against type-4 cardiorenal syndrome through activation of PKM2/PP1/FUNDC1-dependent mitophagy

Metabolic SyndromeCardiomyopathyCardiorenal SyndromesCardiovascular DiseasePharmacologyCardiovascular PharmacologyType-4 Cardiorenal SyndromePkm2/pp1/fundc1-dependent MitophagyVascular BiologyMedicineCardiologyHeart Function